市場調查報告書

纖維蛋白原濃縮製劑的全球市場:成長,趨勢,預測(2020年∼2025年)

Fibrinogen Concentrate Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 964953
出版日期 內容資訊 英文 117 Pages
商品交期: 2-3個工作天內
價格
纖維蛋白原濃縮製劑的全球市場:成長,趨勢,預測(2020年∼2025年) Fibrinogen Concentrate Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 117 Pages
簡介

纖維蛋白原濃縮製劑的市場規模,是對在預測期間內預計將以健全的年複合成長率成長。推動了市場的成長主因出血性疾病的患病率增加以及與纖維蛋白原濃縮物相關的批准數量增加。根據英國醫生血友病協會的一項調查,2018年英國大約有11,089名患有凝血障礙的人。此外,2016年,LFB在歐洲獲得了監管機構批准,可以銷售其產品FibClot。因此,這些因素有望刺激對纖維蛋白原濃縮物的需求。

這份報告提供纖維蛋白原濃縮製劑的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,各適應症·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場推動因素
    • 血液疾病的負擔增加
    • 產品核可的增加
  • 市場阻礙因素
    • 嚴格的法律規範
  • 波特的五力分析

第5章 市場區隔

  • 各適應症
    • 先天性纖維蛋白原缺乏症
    • 外科的治療
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • CSL Behring
    • Hualan Biological Engineering Inc.
    • LFB
    • Molecular Innovations Inc.
    • Octapharma AG
    • Shanghai RAAS

第7章 市場機會及趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 68566

The fibrinogen concentrate market is expected to register a healthy CAGR during the forecast period. The major contributing factor for the growth of this market is the increasing prevalence of bleeding disorders and an increase in the number of approvals related to fibrinogen concentrate. According to the study of United Kingdom Doctor's Hemophilia Association, in 2018, people with coagulation defects were around 11,089 in the United Kingdom. Furthermore, in 2016, LFB received its regulatory approval in Europe to market the product, FibClot. Hence, these factors are expected to fuel the demand for fibrinogen concentrate.

Key Market Trends

Congenital Fibrinogen Deficiency Segment is Expected to Register Significant Growth in the Fibrinogen Concentrate Market

  • Congenital Fibrinogen Deficiency is expected to register a higher growth in the fibrinogen concentrate market owing to the higher prevalence of hemophilia and development in products related to fibrinogen. According to the National Hemophilia Foundation, currently, worldwide the prevalence of hemophilia is more than 400,000. Furthermore, approximately 75% of the affected population still do not receive proper treatment.
  • According to the study published in the year 2019 by the Journal of Thrombosis and Haemostasis, Fibclot and Clottafact, a human fibrinogen concentrate was found to provide effective therapy for the patients with fibrinogen deficiency. Hence, the rising prevalence of bleeding disorders and the safety and efficacy of human fibrinogen concentrate is expected to propel the fibrinogen concentrate market growth in this segment.

North America is Expected to Hold a Significant Share in the Market and this is Expected Remain the Same in the Forecast Period

North America expected to hold a major market share in the global fibrinogen concentrate market due to the increasing burden of bleeding disorders and rising geriatric population. According to the U.S. Census Bureau, in 2018, people aged 65 and above were accounted to be approximately 52 million. Acquired hemophilia, a rare autoimmune disorder, is quite predominant in the geriatric population. According to the National Organization of Rare Disorders, at least 1-2 people per 1,000,000 are affected by the acquired hemophilia in the United States. Around 50% of the affected population the underlying disorders are difficult to identify. Also, according to the National Hemophilia Foundation, Von Willebrand Disease is one of the common bleeding disorders that affects around 1% of the population every year in the United States. Hence, such factors are affected to drive market growth in the North America region.

Competitive Landscape

Various companies are taking initiatives to improve their presence in the market. In 2019, Octapharma AG received approval for Fibryga, a fibrinogen concentrate, to be marketed in 15 European countries. Few of the companies that are currently dominating the market are LFB, Molecular Innovations Inc., Octapharma AG, CSL Behring, Shanghai RAAS, and Hualan Biological Engineering Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Blood Disorders
    • 4.2.2 Increasing Product Approvals
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Framework
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Indication
    • 5.1.1 Congenital Fibrinogen Deficiency
    • 5.1.2 Surgical Procedure
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 CSL Behring
    • 6.1.2 Hualan Biological Engineering Inc.
    • 6.1.3 LFB
    • 6.1.4 Molecular Innovations Inc.
    • 6.1.5 Octapharma AG
    • 6.1.6 Shanghai RAAS

7 MARKET OPPORTUNITIES AND FUTURE TRENDS